Clinical Psychopharmacology

S. Nassir Ghaemi, MD, MPH, is a Professor of Psychiatry and Pharmacology at Tufts University School of Medicine, and a Lecturer on Psychiatry at Harvard Medical School in Boston, Massachusetts. He is also Director of Translational Medicine-Neuroscience at Novartis Institutes for Biomedical Research in Cambridge, Massachusetts. Dr. Ghaemi has been active in clinical psychopharmacology practice and research for over two decades, with specialization in depression and bipolar illness. He holds degrees in philosophy and public health, and is a highly published scientific investigator.

Section I: Basic Psychopharmacology
Chapter 1: A New Psychopharmacology Nomenclature
Chapter 2: Fundamentals of Neurobiology
Chapter 3: Fundamental Psychotropic Drug Structures and Mechanisms

Section II: Clinical Research Concepts for Psychopharmacology
Chapter 4: The Limitations of Clinical Experience
Chapter 5: Evidence-based Medicine: Pro and Con
Chapter 6: Maintenance Treatment Designs: "Enriched," But Not Better
Chapter 7: Negative Studies: The Failure to Know What Isn't Known
Chapter 8: Side Effects and Generalizability: Beyond p-values

Section III: Clinical Psychopharmacology of Drug Classes
Chapter 9: Monoamine Agonists ("Antidepressants"), Including Dopamine Agonists ("Stimulants")
Chapter 10: Dopamine Blockers ("Antipsychotics")
Chapter 11: Second Messenger Modifiers ("Mood Stabilizers")
Chapter 12: Gabaergic Agonists ("Anxiolytics")
Chapter 13: Other Agents (Glutamate Antagonists, Antihistamines, Melatonin Agonists, and Others)
Chapter 14: Drug Class Summaries and Dosing Guidelines
Chapter 15: Index of Selected Commonly Used Drugs with Brief Summaries

Section IV: Clinical Psychopharmacology of Diseases and Syndromes
Chapter 16: Hippocratic Psychopharmacology: A Non-DSM Approach to Practice
Chapter 17: Beyond Symptoms: Diagnostic Validators
Chapter 18: The Concept of a Diagnostic Hierarchy
Chapter 19: Treatment of Affective Illnesses
Chapter 20: Anxiety Conditions
Chapter 21: Treatment of Personality
Chapter 22: Schizophrenia and Schizoaffective Conditions
Chapter 23: Addictions
Chapter 24: PTSD

Section V: Special Topics
Chapter 25: Carcinogenicity of Psychotropic Drugs
Chapter 26: Seasonal Affective Illness
Chapter 27: Suicide
Chapter 28: Children
Chapter 29: Older Persons
Chapter 30: Women
Chapter 31: Ethnic and Racial Groups
Chapter 32: Psychopharmacology in Medical Illnesses
Chapter 33: Polypharmacy
Chapter 34: Cultural Aspects of Psychopharmacology
Chapter 35: Treatment versus Enhancement
Chapter 36: The Pharmaceutical Industry
Chapter 37: Drug Discovery: Future Treatments

Section VI: The Art of Psychopharmacology
Chapter 38: The Diagnostic Interview
Chapter 39: The "Med Check"
Chapter 40: The Placebo Effect
Chapter 41: Legal Aspects of Psychopharmacology Practice
Chapter 42: Psychology of Psychopharmacology
Chapter 43: Innovation in Clinical Practice
Chapter 44: Clinical Cases
Chapter 45: Curbside Consults: Questions and Answers
Chapter 46: Key Research Studies in Clinical Psychopharmacology
Chapter 47: Historical Insights in Psychopharmacology
Chapter 48: Reflections on the Art of Psychopharmacology
Chapter 49: Ten Fallacies and Ten Truths of Psychopharmacology - Explained

Appendices
Appendix I: Mixed States
Appendix II: Bipolar or Borderline?
Appendix III: ADD in Children and Adults
Appendix IV: Schizoaffective Illness